Charité - Universitätsmedizin Berlin
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1710-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.charite.de
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (697 trials with phase data)• Click on a phase to view related trials
Influence of Lung Volume Optimization After Cardiopulmonary Bypass on Cardiac Output and Lung Compliance in Children Undergoing Biventricular Repair of Their Congenital Heart Disease
- Conditions
- Congenital Heart DiseaseCardiopulmonary BypassCardiac SurgeryMechanical VentilationPositive End-expiratory Pressure (PEEP)Lung VolumeLung MechanicsHemodynamic ChangesChildren
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 80
- Registration Number
- NCT07193719
- Locations
- 🇩🇪
German Heart Center of the Charité, Berlin, Germany
The Impact of PRISCUS Medication on Fall Risks
- Conditions
- Fall Injury
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 932912
- Registration Number
- NCT07181993
- Locations
- 🇩🇪
Institute for Medical Informatics | Charité Universitätsmedizin Berlin, Berlin, State of Berlin, Germany
Stimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction
- Conditions
- Neurogenic Bladder Dysfunction
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 150
- Registration Number
- NCT07183683
- Locations
- 🇩🇪
Department for integrative medicine and prevention, Institute for social medicine, epidemiology and health economics, Charité university medicine Berlin, Berlin, State of Berlin, Germany
Evaluation of Needs of Patients and Care-givers During and After Radiotherapy of Patients With Prostate Cancer
- Conditions
- Prostate Cancer Patients
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 60
- Registration Number
- NCT07156903
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
Intensive Care Unit-acquired Heart Failure in Critically Ill: the ICU-HF Study
- Conditions
- Heart FailureICUAW
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 50
- Registration Number
- NCT07094425
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇩🇪Charité - Universitätsmedizin Berlin, Berlin, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 165
- Next
News
Berlin Center for Gene and Cell Therapies Breaks Ground, Creating European Hub for Advanced Therapeutics
Bayer AG, Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health officially began construction of the Berlin Center for Gene and Cell Therapies in September 2025, marking a significant milestone in European biotechnology infrastructure.
TREOS Bio Launches Pivotal Phase II Trial for PolyPEPI1018 in Treatment-Resistant Colorectal Cancer
TREOS Bio has initiated OBERTO-202, a potentially registration-enabling Phase II trial evaluating PolyPEPI1018 combined with toripalimab and standard care in 140 patients with microsatellite stable metastatic colorectal cancer.
Simvastatin Fails to Show Antidepressant Benefits in Major Depression and Obesity Trial
A randomized controlled trial of 161 patients with major depressive disorder and obesity found that adding simvastatin to escitalopram provided no additional antidepressant benefits compared to placebo.
Alys Pharmaceuticals Advances First-in-Class Mast Cell-Selective c-Kit Inhibitor ALY-301 to Clinical Trials for Cold Urticaria
Alys Pharmaceuticals has submitted a Clinical Trial Application to Germany's Paul-Ehrlich-Institut for ALY-301, a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity.
PEARLDIVER: Europe-Wide Platform Trial Aims to Accelerate Depression Treatment Development
The PEARLDIVER project, a Europe-wide platform study, will evaluate multiple depression treatments simultaneously using a shared infrastructure.